Clinical trial
Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan
Name
15-06-274
Description
The primary goal of the analysis is to estimate the diagnostic accuracy of Gallium 68 (68Ga) -DOTATOC PET/CT for detecting neuroendocrine tumors (NETs) compared to conventional imaging techniques such as Magnetic Resonance Imaging (MRI) and Computerized Tomography (CT). Participants with histologically and/or clinically confirmed and/or suspected NET will be enrolled.
Trial arms
Trial start
2016-05-16
Estimated PCD
2017-03-01
Trial end
2017-03-01
Status
Completed
Phase
Early phase I
Treatment
68Ga-DOTATOC
The intervention is to administer 68Ga-DOTATOC PET/CT for detecting NET.
Arms:
68Ga-DOTATOC PET/CT
Other names:
Diagnostic test
Size
11
Primary endpoint
Sensitivity to Correctly Diagnose NET
During imaging process ( approximately 120 minutes)
Eligibility criteria
Inclusion Criteria:
* Signed informed consent.
* Patients of either gender, aged ≥18 years.
* Karnofsky status ≥60.
* Life expectancy of at least 12 weeks.
* Histologically and/or clinically confirmed and/or suspicious of NET.
* A diagnostic CT or MRI of the tumour region or suspected area within the previous 12 weeks prior to dosing day is available.
* Somatostatin-analogue scintigraphy scan with result (positive or negative) within the last 12 weeks.
* Recent Blood test results up to 4-6 weeks as follows:
1. White Blood Cell (WBC): \>2\*109/L
2. Haemoglobin: \>8.0g/Dl
3. Platelets: \>50x109/L
4. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Alkaline phosphatase (AP) each less than, or equal to, 5 times its Upper Limit of Normal (ULN)
5. Bilirubin less than, or equal to, three times its ULN
* Serum creatinine: within normal range or \<120μmol/L for patients aged 60 years or older.
* Negative pregnancy test in women capable of child-bearing.
Exclusion Criteria:
* Known hypersensitivity to Gallium 68, DOTATOC or to any of the excipients of 68Ga-DOTATOC.
* Therapeutic use of any somatostatin analogue, including Sandostatin® LAR (Long Acting Release) (within 28 days) and Sandostatin® (within 2 days) prior to study imaging. If a patient is on Sandostatin® LAR a wash-out phase of 28 days is required before the injection of the study drug.
* Pregnant or breast-feeding women.
* Current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 11, 'type': 'ACTUAL'}}
Updated at
2023-05-09
1 organization
1 product
1 indication
Organization
Montefiore Medical CenterProduct
68Ga-DOTATOCIndication
Neuroendocrine Tumors